हैलो, user_no_name

अब ट्रेड करें

जमा करें

लॉग आउट करें
लॉगिन करें साइन अप करें
HI

भाष

English English (Global)

English English (EU)

English English (UK)

English English (AU)

English English (ZA)

English English (St. Vincent)

Deutsch German

Español Spanish (Latam)

Español Spanish (Spain)

Français French

Dansk Danish

Italiano Italian

Nederlands Dutch

العربية Arabic

Svenka Swedish

Tiếng việt Vietnamese

Bahasa Melayu Malay

ภาษาไทย Thai

繁體中文 Traditional Chinese

简体中文 Simplified Chinese

Tagalog Tagalog

தமிழ் Tamil

हिन्दी Hindi

Português Portuguese

Bahasa Indonesia Indonesian

한국어 Korean

English English (BVI)
बाज़ार

प्रोडक्ट्स

फ़ॉरेक्स

शेयर्स

कमोडिटीज़

सूचकांक

क्रिप्टोकरेंसी

ETFs

बॉन्ड्स
ट्रेडिंग

ट्रेडिंग प्लेटफ़ॉर्म्स

वेब प्लेटफ़ॉर्म

ऐप

TradingView

MT4

MT5

सोशल ट्रेडिंग

Trading Central

ट्रेडिंग टूल्स

CFD ट्रेडिंग कैल्कुलेटर

फ़ॉरेक्स मार्जिन कैल्कुलेटर

कमोडिटीज़ मुनाफ़ा कैल्कुलेटर

फ़ॉरेक्स मुनाफ़ा कैल्कुलेटर

इकॉनोमिक कैलेंडर

ट्रेडिंग की जानकारी

CFD ट्रेडिंग

CFD अस्सेट लिस्ट

ट्रेडिंग की शर्तें

ट्रेडिंग का समय

एक्सपायरी की तारीखें

आगामी ट्रेडिंग छुट्टियाँ

ट्रेडिंग के फ़ीचर्स

बाज़ार की गहराई
सीखें

ट्रेड करना सीखें

शिक्षा केंद्र

ट्रेडिंग की मूल बातें

समाचार और विश्लेषण

समाचार
भागीदारी

संबंध

IB
इसके बारे में

Markets.com के बारे में

Markets.com क्यों

वैश्विक पेशकश

हमारा ग्रुप

अवॉर्ड्स और मीडिया

हेल्प और सपोर्ट

सपोर्ट से संपर्क करें

शिकायतें

डेटा और सुरक्षा

सुरक्षा ऑनलाइन

कुकी डिस्क्लोज़र

कानूनी पैक

कानूनी पैक

अधिनियम

खोजें

भाष

लॉगिन करें साइन अप करें

Eli Lilly's Orforglipron vs. Novo Nordisk's Oral Semaglutide: A Closer Look

शुक्रवार Sep 26 2025 08:30

2 मिनट

सामग्री की तालिका

1. Eli Lilly's Orforglipron vs. Novo Nordisk's Oral Semaglutide: A Closer Look
1.1 Eli Lilly's Trial Data
1.2 Context Matters
1.3 The Takeaway

Eli Lilly's Orforglipron vs. Novo Nordisk's Oral Semaglutide: A Closer Look

Eli Lilly recently released top-line results from a head-to-head trial of its oral GLP-1 pill, orforglipron, compared to Novo Nordisk's oral version of semaglutide, and claimed superiority in treating type 2 diabetes. According to the press release, "In key secondary endpoints, orforglipron was also superior to oral semaglutide for weight loss." Neither pill is yet available for sale, but do the test results mean it's already game over in the battle between the two?

Eli Lilly's Trial Data

It's essential to never take the headline data of clinical trials as gospel, and that's especially relevant in this case. First, this head-to-head trial was aimed at lowering A1C levels (a measure of blood sugar), and, on this basis, the reported results do support the idea of superiority for Lilly's drug. For example, at the highest dosage of orforglipron (36mg), there was a 2.2% reduction in A1C compared to a 1.4% reduction in A1C in oral semaglutide at the highest dosage (14mg). However, data about the secondary endpoint of weight loss needs to be put into context. Eli Lilly claims that the highest dosage of orforglipron (36mg) produced an average weight loss of 9.2%, compared to a 5.3% reduction for the highest dosage (14mg) of oral semaglutide.

Context Matters

But here's the thing. Novo Nordisk is trialing oral semaglutide at a much higher dosage (25mg) in obesity than the 14mg dosage used in the Eli Lilly trial. In fact, Novo Nordisk recently released results from its Oasis 4 phase 3 trial in obesity at the 25mg dosage, reporting an average weight reduction of 16.6%.

The Takeaway

While the trial is good news for Eli Lilly in treating type 2 diabetes, it should not be taken as evidence of orforglipron winning out over oral semaglutide in terms of efficacy in the more lucrative obesity indication.

Risk Warning and Disclaimer: This article represents only the author’s views and is for reference only. It does not constitute investment advice or financial guidance, nor does it represent the stance of the Markets.com platform. Trading Contracts for Difference (CFDs) involves high leverage and significant risks. Before making any trading decisions, we recommend consulting a professional financial advisor to assess your financial situation and risk tolerance. Any trading decisions based on this article are at your own risk.